Abstract
Currently only a fraction of patients with non-small cell lung cancer (NSCLC) experience durable clinical benefit (DCB) from immunotherapy, robust biomarkers to predict response prior to initiation of therapy are an emerging clinical need. PD-L1 expression status from immunohistochemistry is the only clinically approved biomarker, but a non-invasive complimentary approach that could be used when tissues are not available or when the IHC fails and can be assessed longitudinally would have important implications for clinical decision support. In this study, 18F-FDG-PET/CT images and clinical data were curated from 697 NSCLC patients from three institutions. Utilizing PET/CT images, a deeply-learned-score (DLS) was developed by training a small-residual-convolutional-network model to predict the PD-L1 expression status, which was further used to predict DCB, progression-free survival (PFS), and overall survival (OS) in both retrospective and prospective test cohorts of immunotherapy-treated patients with advanced stage NSCLC. This PD-L1 DLS significantly discriminated PD-L1 positive and negative patients (AUC≥0.82 in all cohorts). Further, higher PD-L1 DLS was significantly associated with higher probability of DCB, longer PFS, and longer OS. The DLS combined with clinical characteristics achieved C-indices of 0.86, 0.83 and 0.81 for DCB prediction, 0.73, 0.72 and 0.70 for PFS prediction, and 0.78, 0.72 and 0.75 for OS prediction in the retrospective, prospective and external cohorts, respectively. The DLS provides a non-invasive and promising approach to predict PD-L1 expression and to infer clinical outcomes for immunotherapy-treated NSCLC patients. Additionally, the multivariable models have the potential to guide individual pre-therapy decisions pending in larger prospective trials.
Statement of Significance PD-L1 expression status by immunohistochemistry (IHC) is the only clinically-approved biomarker to trigger immunotherapy treatment decisions, but a non-invasive complimentary approach that could be used when tissues are not available or when the IHC fails and can be assessed longitudinally would have important implications for clinical decision support. Utilizing PET/CT images, we developed and tested a convolutional neural network model to predict PD-L1 expression status with high accuracy in cohorts from different institutions. And the generated signature may serve as a prognostic biomarker for immunotherapy response in patients with NSCLC, and outperforms the clinical characteristics.
Competing Interest Statement
Robert J. Gillies declared a potential conflict with HealthMyne, Inc [Investor (major), Board of Advisors (uncompensated)]. Evangelia Katsoulakis has no direct conflict of interest but does have stock ownership in Abbvie, Alexion Pharmaceuticals, Biogen and research clinical trial funding with Advantagene. Jhanelle E. Gray reports receiving commercial research grants from AstraZeneca, Merck, Array, Epic Sciences, Genentech, Bristol-Myers Squibb, BI, Trovagene, and Novartis, and is a consultant/advisory board member for AstraZeneca, Janssen, Genentech, Eli Lilly, Celgene, and Takeda, and other remuneration from Genentech, AstraZeneca, Merck, and Lilly/Genenech. The remaining authors declare no conflict of interest. Contents of this research do not represent the views of the Department of Veterans Affairs or the United States Government.
Funding Statement
This study was funded by U.S. Public Health Service research grant U01 CA143062 and R01 CA190105 (principal investigator Dr. Gillies). This material includes work supported with resources and the use of facilities at the James A. Haley Veterans' Hospital.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards at Shanghai Pulmonary Hospital, University of South Florida and James A. Haley Veterans' Hospital, and was conducted in accordance with ethical standards of the 1964 Helsinki Declaration and its later amendments. The requirement for informed consent was waived, as no PHI is reported.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The PET/CT imaging data and clinical information are not publicly available for patient privacy purposes, but are available from the corresponding authors upon reasonable request (R.J.G, and M.B.S).
